Year
2020
Status
Active
Team
Field
Oncology
Location
Boston (US)
Fund
BGV IV
Tiga TX
Tiga TX develops an IgA therapeutic monoclonal antibody platform for the treatment of solid tumors.
2020
Active
Oncology
Boston (US)
BGV IV
Tiga TX develops an IgA therapeutic monoclonal antibody platform for the treatment of solid tumors.